Diagnostic Center | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
The company has raised US$4.5 million in funding for its AI operating system
Yesafili, received marketing authorization approval from the European Commission for the European Union
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
US business grew by +12.8% YoY
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Dr. Reddy’s maintains that the allegations against it lack merit and will vigorously defend the litigation
General Medicine grows 5% and Vaccines 10% led by Shingrix
Subscribe To Our Newsletter & Stay Updated
